D
11.90
0.02 (0.17%)
| Penutupan Terdahulu | 11.88 |
| Jumlah Dagangan | 132,380 |
| Harga / Buku (P/B) | 4.87 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -3,534.93% |
| EPS Cair (TTM) | -5.75 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -46.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 251.79% |
| Nisbah Semasa (MRQ) | 0.720 |
| Aliran Tunai Operasi (OCF TTM) | -89.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.08 M |
| Pulangan Atas Aset (ROA TTM) | -72.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -198.47% |
AISkor Stockmoo
| Nilai 35% | -5.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -5.0 |
| Masa 35% | 0.8 |
| AI Technical info | NA |
| Osilator Teknikal info | 2.0 |
| Purata Bergerak Teknikal info | -1.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Sentimen Berita info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -23.0% |
| Persetujuan Tonggak | ×1.11 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 4.9 |
| Skor Akhir | -1.98 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | DBV Technologies S.A. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| DBVT | - | - | - | 4.87 |
| TRML | 1 B | - | - | 4.76 |
| ABEO | - | - | - | 1.04 |
| CTNM | - | - | - | 1.69 |
| FTRE | - | - | - | 3.88 |
| JANX | - | - | - | 0.810 |
|
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Institusi | 1.81% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years
Châtillon, France, November 12, 2026 DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years Additional VITESSE data being presented at 2026 ACAAI Annual Scientific Meeting support safety and efficacy findings from the phase 3… |
| 09 Nov 2026 | Yahoo Finance |
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears
DBV Technologies (NASDAQ:DBVT) is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics license application, executives said at Guggenheim’s Healthcare Innovation Conference. CEO Daniel Ta… |
| 04 Nov 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Advance Sharply in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking significantly highe… |
| 03 Nov 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower late… |
| 02 Nov 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts began the week tracking higher la… |
| 02 Nov 2026 | Yahoo Finance |
DBV Technologies to Participate in Upcoming November Investor Conferences
Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at… |
| 30 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
European equities traded in the US as American depositary receipts were down 0.59% to 1,896.05 on th… |
| 29 Oct 2026 | Yahoo Finance |
DBV Technologies (DBVT) Q3 2026 Earnings Call Transcript
Net loss widened to $64.5 million as company scales commercial operations. |
| 29 Oct 2026 | Yahoo Finance |
DBV Technologies shares slide 8% on going-concern warning, wider Q3 loss
Investing.com -- Shares of French biotech DBV Technologies tumbled over 8% on Thursday, a day after it warned of “substantial doubt” about its ability to keep operating, a month after it filed for U.S. approval of its peanut allergy patch for young children. |
| 28 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Steady in Wednesday Trading
European equities traded in the US as American depositary receipts were little changed around 1,893… |
| 28 Oct 2026 | Yahoo Finance |
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review Accelerated Commercial Readiness… |
| 28 Oct 2026 | Yahoo Finance |
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
DBV Technologies (NASDAQ:DBVT) said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a potential commercial launch and addressing manufacturing readiness at its contr… |
| 27 Oct 2026 | Yahoo Finance |
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a… |
| 27 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking lower late Tuesday… |
| 23 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were trending lower late Friday m… |
| 22 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday… |
| 20 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Tuesday… |
| 16 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
European equities traded in the US as American depositary receipts were tracking higher late Friday… |
| Papar semua | ||
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |